Literature DB >> 3621151

Decreased cisplatin uptake by resistant L1210 leukemia cells.

R A Hromas, J A North, C P Burns.   

Abstract

Cisplatin resistance remains poorly understood compared to other forms of anti-neoplastic drug resistance. In this report radiolabeled cisplatin and rapid separation techniques were used to compare drug uptake by L1210 leukemia cells that are sensitive (K25) or resistant (ZCR9) to cisplatin. Uptake of cisplatin by both cell lines was linear without saturation kinetics up to 100 microM. The resistant ZCR9 cells had 36-60% reduced drug uptake as compared to its sensitive parent line, K25. In contrast, there was no difference in the rate of efflux. We conclude that a decreased rate of uptake is one possible mechanism of cellular cisplatin resistance.

Entities:  

Mesh:

Substances:

Year:  1987        PMID: 3621151     DOI: 10.1016/0304-3835(87)90091-7

Source DB:  PubMed          Journal:  Cancer Lett        ISSN: 0304-3835            Impact factor:   8.679


  16 in total

1.  Glutathione content is correlated with the sensitivity of lines of PC12 cells to cisplatin without a corresponding change in the accumulation of platinum.

Authors:  K Ikeda; K Miura; S Himeno; N Imura; A Naganuma
Journal:  Mol Cell Biochem       Date:  2001-03       Impact factor: 3.396

2.  A mathematical model for cisplatin cellular pharmacodynamics.

Authors:  Ardith W El-Kareh; Timothy W Secomb
Journal:  Neoplasia       Date:  2003 Mar-Apr       Impact factor: 5.715

Review 3.  Role of copper transporters in platinum resistance.

Authors:  Deepak Kilari; Elizabeth Guancial; Eric S Kim
Journal:  World J Clin Oncol       Date:  2016-02-10

4.  Predicting chemotherapeutic response to small-cell lung cancer of platinum compounds by thallium-201 single-photon emission computerized tomography.

Authors:  Y Tokuchi; H Isobe; H Takekawa; T Hanada; T Ishida; S Ogura; K Itoh; M Furudate; K Saito; Y Kawakami
Journal:  Br J Cancer       Date:  1998-04       Impact factor: 7.640

5.  Short-term cis-diamminedichloroplatinum(II) accumulation in sensitive and resistant human ovarian carcinoma cells.

Authors:  S C Mann; P A Andrews; S B Howell
Journal:  Cancer Chemother Pharmacol       Date:  1990       Impact factor: 3.333

6.  Cross-resistance between cisplatin, antimony potassium tartrate, and arsenite in human tumor cells.

Authors:  P Naredi; D D Heath; R E Enns; S B Howell
Journal:  J Clin Invest       Date:  1995-03       Impact factor: 14.808

Review 7.  Cellular accumulation of the anticancer agent cisplatin: a review.

Authors:  D P Gately; S B Howell
Journal:  Br J Cancer       Date:  1993-06       Impact factor: 7.640

Review 8.  Can pharmacogenetics explain efficacy and safety of cisplatin pharmacotherapy?

Authors:  Angela Roco; Juan Cayún; Stephania Contreras; Jana Stojanova; Luis Quiñones
Journal:  Front Genet       Date:  2014-11-14       Impact factor: 4.599

9.  Reduced drug accumulation as a major mechanism of acquired resistance to cisplatin in a human ovarian carcinoma cell line: circumvention studies using novel platinum (II) and (IV) ammine/amine complexes.

Authors:  S Y Loh; P Mistry; L R Kelland; G Abel; K R Harrap
Journal:  Br J Cancer       Date:  1992-12       Impact factor: 7.640

10.  Evaluation of novel ammine/amine platinum (IV) dicarboxylates in L1210 murine leukaemia cells sensitive and resistant to cisplatin, tetraplatin or carboplatin.

Authors:  R M Orr; C F O'Neill; M C Nicolson; C F Barnard; B A Murrer; C M Giandomenico; J F Vollano; K R Harrap
Journal:  Br J Cancer       Date:  1994-09       Impact factor: 7.640

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.